BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten
Company Sees Opportunity For A Similar Ramp-Up For The Cardiovascular Drug
Executive Summary
Paying $13.1bn for MyoKardia and its potential first-in-class HCM drug, BMS sees a blockbuster sales opportunity that it will grow gradually. MyoKardia team will be absorbed into BMS, Caforio says.
You may also be interested in...
Cytokinetics Gets A Belated Christmas Present
Aficamten hits nicely in its pivotal hypertrophic cardiomyopathy trial, and a deal will surely follow.
LianBio Eyes ‘Strategic Review’ As It Hands Camzyos Asia Rights Back To MyoKardia Parent BMS
BMS, which acquired MyoKardia in 2020 months after LianBio acquired rights in certain Asia-Pacific territories, said the deal would help expand its footprint in China.
BMS Revs R&D Engine To Advance 10 New Drug Candidates Annually
Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.